Purpose：Midostaurin (PKC412) is a multi-target protein kinase inhibitor for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Structural formula:
Properties
Summary
Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus, and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor, FLT3).
After successful Phase II clinical trials, a Phase III trial for AML has started in 2008. It is testing midostaurin in combination with daunorubicin and cytarabine. In another trial, the substance has proven ineffective in metastatic melanoma.
Manufacturing
